SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2017 financial results on Wednesday, August 9, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
|Date:||Wednesday, August 9, 2017|
|Time:||4:30 p.m. ET|
|Dial-in numbers:||+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)|
|Live webcast:||Retrophin.com in the "Events & Presentations" section of the "Investors" page|
A replay of the call will be available from 7:30 p.m. ET, August 9, 2017 to 7:30 p.m. ET, August 16, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 60017665.
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 (fosmetpantotenate) for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®.
Contact: Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 IR@retrophin.com